InvestorsHub Logo
Followers 73
Posts 10908
Boards Moderated 1
Alias Born 10/02/2009

Re: None

Friday, 08/09/2019 11:44:15 PM

Friday, August 09, 2019 11:44:15 PM

Post# of 1067



Joseph Moscato - Chief Executive Officer, President and Chairman of the Board

Mr. Moscato has over 30 years of experience in healthcare, sales and marketing, distribution management, and finance. Mr. Moscato brings his marketing and advertising acumen to drug discovery and diagnostic & treatment development and commercialization. Since 2009, Mr. Moscato has been working as an exclusive consultant to the Company. Mr. Moscato has originated and negotiated several licensing deals with the top biopharmaceutical companies; has advised on equity financings totaling over $300 million, and has implemented the broad strategic vision for the Company. Mr. Moscato has worked and consulted for Pfizer in several capacities from sales and marketing to new drug discovery & development for licensing. He has worked with other biopharmaceutical companies such as GlaxoSmithKline, Johnson & Johnson, Parke-Davis, Amgen and others. Mr. Moscato has consulted for several healthcare focused private equity, hedge funds and family offices.

Mr. Moscato also owned several advertising and marketing agencies focused on media, entertainment, and healthcare with clients ranging from Motorola, Chadmoore Wireless, Nextel, Cannon, Sharp, GlaxoSmithKline, Pfizer, and other biopharmaceutical companies. Mr. Moscato’s agency was acquired by William Douglas McAdams, one of the largest independent healthcare advertising and marketing agencies.

Terry Thompson - Chief Operating Officer

Terry Thompson brings a wealth of experience and expertise in healthcare, providing executive leadership in pharmacy benefits management, network administration, claims processing, and distribution & logistics for drugs, durable medical equipment (DME), and infusion therapy, as illustrated by his impressive 35-year career.
Mr. Thompson started his career working with FedEx, one of the most successful startups of our era, from the company’s pre-IPO infancy to its proven “changing the way the world does business” outcome. After leaving FedEx, he used his expertise in healthcare, focusing on the pharmacy sector, to participate in the creation of the nation’s first Pharmacy Benefits Manager (PBM), Medco Containment Services, ultimately serving as Executive Vice President of Merck-Medco post-acquisition, and President of National Rx Services and Paid Prescriptions. Following his work with Medco, Mr. Thompson was COO of Synetic, Inc.’s Institutional Pharmacies, where he assimilated numerous acquired full service companies. Additionally, he brings relevant experience as Chief Operating Officer of Merit Behavioral Care Corp., a KKR buyout and largest Specialty HMO at the time, Chief Executive Officer of Closer HealthCare, Inc., a DME and Diabetic Supply Company, supporting the NIH’s ACCORD and BARI IID clinical trials, and Independent Director of ProVantage Health, a billion dollar publicly traded PBM. For the last several years, Mr. Thompson has provided consulting services to C-Level executives and their teams, primarily in healthcare.

Andrew Ro - Chief Investment Officer and a Director

Mr. Ro has over 20 years’ experience in the financial markets ranging from trading global futures and equity markets, senior secured debt, convertible securities, private investments in public equities (PIPEs) and investing. Mr. Ro was a Consultant and Registered Representative with boutique investment and merchant banks where he consulted and advised US and international companies on capital markets, operational, and regulatory issues as well as being involved in capital raising, mergers & acquisitions, and strategic implementation. Mr. Ro was a Partner with an active Investment Fund where he was involved in originating, structuring, negotiating and closing financing transactions providing growth capital, acquisition financing, recapitalization, restructuring and general working capital to late-stage venture, distressed and middle market companies across all industries and sectors. Mr. Ro originated and structured over $2 billion in total commitments and managed a portfolio of over $650 million in investments. Mr. Ro graduated from George Mason University with a Bachelor in Science in Economics. He also held Series 3, Series 7, and Series 63 licenses.

Mark Corrao - Chief Financial Officer and Treasurer

Mr. Corrao has experience in financial management with a proven track record of raising capital and extraordinary bottom line management. He has been involved in the initial registration of numerous public companies and subsequent SEC quarterly and annual reporting and has developed, authored and presented numerous business plans and models inclusive of budgets, forecasts, cash flow, cash management and investment strategies. From 2012 to present he has been a Managing Director and CFO of The Mariner Group LLC, which has merged with the CFO Squad, creating a much larger and diverse multi-talented organization. The CFO Squad is a financial and business advisory firm providing outsourced and part-time CFO services for emerging to midsized companies (both private and public) in a wide range of businesses and industries. He is the Chief Financial Officer for a pharmaceutical company specializing in the research and development of novel and new therapeutic agents designed to reduce oxidative stress and act as immune modulators and Neuroprotectants. From 2010-12, he served as Chief Financial Officer of New York Business Efficiency Experts, Inc. which provides professional services in the financial areas of accounting, taxation, auditing, venture capital and SEC registrations (reporting). He served as a Director and Chief Financial Officer for a manufacturer of proprietary software for the prevention of identity theft and the protection of computer systems from unauthorized access. Additionally, Mr. Corrao is currently the CFO for a software company.

Dr. Jason B. Terrell, MD. - Chief Scientific Officer and Chief Medical Officer

Dr. Terrell has extensive expertise in the pharmaceutical and medical diagnostic device industry in the areas of business development, clinical trial organization, regulatory affairs and commercialization strategies. Dr. Terrell has served as medical director and chief medical officer for several public and private companies like VolitionRx, a NYSE traded international medical diagnostic company. Dr. Terrell previously served as a Corporate Medical Director for Any Lab Test Now, the nation’s largest direct to consumer medical testing franchise, where he supervised clinical operations for over 70 locations throughout the United States. Dr. Terrell is a summa cum laude graduate from Hardin-Simmons University with a degree in Biochemistry. He graduated as recipient of the Holland Medal of Honor for the top graduate in the School of Science and Mathematics. Dr. Terrell was honored with the Hardin-Simmons University Outstanding Young Alumni Award and currently serves on the University’s Board of Development. Dr. Terrell is an Assistant Clinical Professor of Oncology at the University of Texas Dell Medical School in Austin, Texas, he attended The University of Texas School of Medicine in Houston and received General Medicine Internship and Pathology Residency training at the Texas Tech University Health Sciences Center.

Richard Purcell - Senior Vice-President of Research & Drug Development

Mr. Purcell has over 30 years of experience in consulting and advising emerging biopharmaceutical and technology companies on new business strategy, operations management, clinical development of novel compounds, data solutions for clinical and medical applications, patient engagement & communication, medical education for professionals and consumers, and data analytics for outcomes research. Mr. Purcell oversaw strategic planning, clinical operations, data management, regulatory filings, and R&D and was involved with business development and out-licensing activities for the company’s technology platform.

He started his career as a molecular biologist, where he developed and patented a second generation TPA with increased half-life. He also worked at a major pharmaceutical company where he conducted primary research and published several manuscripts on the topics of AIDS and immunomodulators. Mr. Purcell also headed the Life Sciences Consulting Group for Kline and Company, where he conducted market, technology and business analysis for the commercial development of pharmaceutical and biotechnology products for therapeutic and diagnostic applications.

Rich graduated with a degree in Biochemical Sciences from Princeton University, and attended Rutgers Graduate School of Management majoring in marketing and finance. He is a member of NJTC, HIMSS, the Patient-Centered Primary Care Collaborative, the Drug Information Association and the Licensing Executives Society. He is also an Adjunct Professor of Biology at Monmouth University where he developed and teaches The Business of Biotechnology.

Dick Suedkamp - Executive Vice President, Finance and Accounting

Dick Suedkamp is the EVP of Finance at Nugenerex, where he manages the company's finance and accounting functions. Prior to Nugenerex, Dick spent two years in finance and accounting leadership roles at Veneto Holdings and most recently served as Chief Financial Officer. During his tenure, Dick was instrumental in building out the finance and accounting business support capabilities and function at Veneto. Dick also spent almost 12 years in public accounting in the Big 4. He received his bachelor of business administration and master of professional accounting degrees from the University of Texas at Austin and is licensed as a CPA in the state of Texas.

Steve Worster - Chief Compliance Officer

Mr. Worster has more than fifteen years of healthcare compliance experience including holding executive level positions with Cardinal Health and HMS. As part of his prior compliance rolls Mr. Worster has also been responsible for managing data security, physical security and business continuity programs. In addition to leading the compliance function, Mr. Worster will also act as the company’s Chief Privacy Officer. Prior to working in Compliance, Mr. Worster worked as a police officer for six years in suburban Columbus, Ohio and is a Veteran of the Air Force. He earned BA from The Ohio State University and his Juris Doctorate from Villanova University’s Charles Widger School of Law.

Brad Guy - Chief Human Resource Officer

Mr. Guy brings deep domain knowledge and experience in the areas of HR Strategy, Compensation and Benefits, Recruitment & Selection and Organization Design. He was previously the Vice President of Human Resources at Veneto Holdings, LLC before joining Generex as our Chief Human Resources Officer. Mr. Guy brings a wealth of experience in Healthcare, Financial Services, Strategy Consulting and Consumer Products having worked for publicly traded companies such as, Alcon Laboratories, a subsidiary of Novartis Pharmaceuticals, Yum! Brands, Inc., CapitalOne as well as diversified money managers like Highland Capital Management, LLC and strategy consulting firms. Mr. Guy began his career in management consulting and executive search. He earned his MBA with distinction from the University of Dallas and his BBA from the University of North Texas.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.